Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans
Open Access
- 9 January 2026
- journal article
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 41 (6) , 330-338
Abstract
Molnupiravir (MOV) is a prodrug of N-hydroxycytidine (NHC), an analog of the endogenous ribonucleoside cytidine that can be administered orally. MOV is used for treating patients infected by SARS-CoV-2, the coronavirus responsible for COVID-19. MOV and NHC are mutagenic in bacterial and in mammalian cell cultures, yet both chemicals have been negative or equivocal in nonclinical in vivo models of mutagenesis. We designed and validated a novel error-corrected sequencing (ECS) method for detecting single basepair substitutions in tissue samples obtained from genetically heterogeneous humans. The software used for this ECS method is available for free from a public online repository and it is suitable for analysis of in vivo and in vitro derived samples collected in various experimental scenarios. We recruited two groups of patients having COVID-19 1–3 years ago, one group that received a full course of MOV therapy and the other group (matched for age and COVID-19 diagnosis date) that did not receive MOV. Using the ECS method, we determined the frequencies of basepair substitutions in nucleated cells isolated from peripheral blood of the patients. There was no observed difference in the frequency of mutations, the types of mutations, or mutational spectra between the MOV and the control groups. Also, the spectra of mutations in the MOV group did not show any evidence of the mutational signature expected from exposures to MOV or NHC based on data from mammalian cell culture models. Within the limits of this study, the dose of MOV authorized for the treatment of COVID-19 under emergency use authorization appears to have no mutational consequences for treated patients.Keywords
Funding Information
- U.S. Food and Drug Administration’s National Center for Toxicological Research
- University of Maryland, Baltimore’s participation (U01FD005946)
This publication has 21 references indexed in Scilit:
- Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencingToxicology Letters, 2025
- Whole-genome high-fidelity sequencing: A novel approach to detecting and characterization of mutagenicity in vivoMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2023
- Evaluation of the mutagenic effects of Molnupiravir and N4‐hydroxycytidine in bacterial and mammalian cells by HiFi sequencingEnvironmental and Molecular Mutagenesis, 2022
- Genome‐wide detection of ultralow‐frequency substitution mutations in cultures of mouse lymphoma L5178Y cells and Caenorhabditis elegans worms by PacBio sequencingEnvironmental and Molecular Mutagenesis, 2022
- PacBio sequencing detects genome‐wide ultra‐low‐frequency substitution mutations resulting from exposure to chemical mutagensEnvironmental and Molecular Mutagenesis, 2021
- The repertoire of mutational signatures in human cancerNature, 2020
- Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single and split doses of N-ethyl-N-nitrosoureaMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009
- N4-hydroxycytidine: A mutagen specific for at to GC transitionsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1980
- The efficiency and extent of mutagenic activity of some new mutagens of base-analogue typeMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1978
- N4-hydroxycytidine — A new mutagen of a base analogue typeBiochemical and Biophysical Research Communications, 1974